Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Therapeutic Agent Identification
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institutes of Health, including the National Institute of Neurological Disorders and Stroke, National Institute on Aging, and other participating centers under the NIH Helping to End Addiction Long Term (HEAL) initiative, are aiming to support projects focused on developing assays—whether in vitro, ex vivo, or in vivo—and conducting screening efforts to identify and characterize potential therapeutic agents. These agents target disorders supported by the participating institutes or non-opioid analgesics with minimal addiction risk, encompassing small molecules and biologics. The use of innovative New Approach Methodologies (NAMs) in assay development is encouraged when suitable. At present, applications are not being accepted; the announcement serves as an advance notice to provide prospective applicants adequate time to establish collaborations and prepare strong project proposals. This initiative, titled Innovation Grants to Nurture Initial Translational Efforts (IGNITE), reflects commitment to translational research efforts facilitating early-stage therapeutic development. Inquiries may be directed to the designated contact provided by the National Institute of Neurological Disorders and Stroke.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute of Neurological Disorders and Stroke, National Institute of Aging, the NIH Helping to End Addiction Long Term (HEAL) initiative, and other participating NIH Institutes/Centers (ICs) seek to support applications to develop in vitro, ex vivo or in vivo assays and conduct screening efforts with the goal of identifying and characterizing potential therapeutic agents for disorders or diseases supported by participating ICs, or for non-opioid analgesic therapeutics with little or no addiction liability as a part of the NIH Helping to End Addiction Long Term (HEAL) initiative. Therapeutic agents include small molecules and biologics. Assays utilizing New Approach Methodologies (NAMs) may be used when appropriate.
Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
